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Introduction  19 
Acute ischemic stroke (AIS) is the leading cause of disability in adults worldwide and has the 20 
second highest mortality of all cardiovascular diseases[1]. The burden of stroke is likely to 21 
increase significantly during the next decades, primarily due to population growth and aging[2]. 22 
Given the detrimental impact of stroke on healthcare (costs) and patient well-being, it is 23 
imperative to explore opportunities for novel therapies to add to the current treatment to further 24 
minimize neurological injury.  25 
During an ischemic stroke, occlusion of a cerebral artery abrogates cerebral perfusion, causing 26 
brain tissue distal from the occlusion to become deprived of oxygen and nutrients, ultimately 27 
leading to ischemic injury. Surrounding the ischemic core an area called the penumbra contains 28 
potentially reversible injured brain tissue, which may remain viable for several hours. Whilst 29 
the time window to attenuate the detrimental impact of an ischemic stroke seems limited to six 30 
hours after onset of AIS[3, 4], recent research suggests that subgroups may benefit up to 24 31 
hours[5, 6]. This time window of 6-24 hours offers perspective for hospital-based, additional 32 
therapies to reduce ischemic injury and minimize clinical deterioration in AIS patients.  33 
This review focuses on remote ischemic conditioning (RIC) as an additive therapy to improve 34 
clinical outcomes in AIS patients, both when applied as a single as well as repeated bouts. RIC 35 
refers to the application of several cycles of brief ischemia and reperfusion to a limb (using a 36 
blood pressure cuff). Pre-clinical work revealed this stimulus to reduce neural damage after 37 
reperfusion[7-11], validating the concept that RIC may have clinical potential in AIS. RIC 38 
therefore represents a simple, low cost therapeutic strategy that may salvage brain tissue in the 39 
penumbral area. In this review, we will summarize (pre)clinical evidence for the efficacy of 40 
RIC as an additional therapy in AIS patients. 41 
 42 
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Methods 43 
A formal systematic review was not performed because of the heterogeneity of the studies and 44 
recently published systematic reviews on preclinical[12] and clinical studies[13]. Nonetheless this 45 
review tested for the rigor, quality and appropriateness of the available studies that examined 46 
the (pre)clinical efficacy of RIC in AIS patients by providing detailed information for each 47 
individual study. In addition, this narrative review also highlights remaining knowledge gaps 48 
to give directives for future research. . The primary search originally occurred in September 49 
2018, and was repeated in March 2019, and used keywords related to ischemic conditioning 50 
and stroke in Pubmed (i.e., "ischemic conditioning" OR "ischemic conditioning" AND 51 
"stroke") and were included if they (1) were written in English, (2) were performed in either 52 
humans or animals, and (3) primarily focused on the application of remote ischemic 53 
conditioning as a therapeutic strategy in stroke (models).  From these initial articles, reference 54 
lists were scanned for additional suitable articles to include in this review. Eventually, this 55 
yielded 34 suitable articles, of which 27 were performed in a preclinical setting and 7 were 56 
performed in humans.   57 
 58 
What is remote ischemic conditioning?   59 
Ischemic conditioning was first introduced in the field of cardiology in 1986[14] by Murry et al., 60 
who found that short repetitive bouts of occlusion and reperfusion of a coronary artery in dogs 61 
subsequently protected the heart against a myocardial infarction. The first evidence for the 62 
remote application of ischemic conditioning was discovered in 1993 in a study that showed that 63 
ischemic conditioning of a coronary artery also protected remote cardiac tissue not directly 64 
supplied by this artery.[15] This initiated research that allowed the application of RIC to become 65 
clinically applicable, especially since the observation that also RIC applied to a limb (using a 66 
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blood pressure cuff) effectively protected remote tissue, such as the brain, against prolonged 67 
ischemia (e.g. during/after AIS) and ischemia reperfusion (I/R) injury (e.g. induced by the 68 
revascularization procedure)[16]. Whilst initial studies have primarily explored the effects of 69 
RIC in patients with coronary heart disease, with (pre)clinical studies showing conflicting 70 
results [17-22], more recent studies have also explored the potential of RIC in AIS patients[7-11].  71 
The application of RIC can be divided into three variants that differ based on the timing in 72 
relation to AIS: before, during or after an ischemic event[23], which are respectively called 73 
remote ischemic pre-conditioning (rIPreC), per-conditioning (rIPerC) and post-conditioning 74 
(rIPostC). Although the timing of these three types of RIC differ, previous meta-analyses 75 
suggest that the neuroprotective effects of the distinct types of RIC are comparable[24, 25] (figure 76 
1). Furthermore, even though the exact mechanisms by which RIC reduces I/R injury in the 77 
brain remain unclear, the currently accepted hypothesis is that transient I/R injury induced by 78 
pre-, per- and post-conditioning all induce the release of humoral factors and local autacoids 79 
(e.g. nitric oxide, nitrite and adenosine), which activate afferent neural and/or humoral 80 
pathways [9]. After signal transmission[9, 26], RIC reduces I/R-induced oxidative damage[11] and 81 
suppresses inflammatory responses in the brain which can last up to days after 82 
revascularization[16]. More detailed discussion of potential mechanisms explaining the potential 83 
benefits of RIC to reduce I/R in the brain can be found elsewhere in excellent and detailed 84 
reviews covering this topic[9, 12]. Given this comparable mechanism and the sparsity of data in 85 
the (clinical) field, we have included all three variants of RIC in our review. 86 
 87 
What is the evidence for RIC as an additional therapy in AIS?  88 
Evidence for conditioning of the brain from preclinical studies in animals  89 
Is a single bout of RIC effective in the animal brain?  90 
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A single bout of RIC activates at least two distinct time frames of protection against I/R injury 91 
of the brain[27]. The initial protection is short lasting (~2 hours) and occurs immediately after 92 
RIC. The delayed form of protection reappears after 12-24 hours and lasts 48-72 hours[28].  A 93 
substantial amount of preclinical studies has investigated the protective effect of single RIC in 94 
focal ischemia models using direct cerebral artery occlusion. The first evidence for the 95 
protective effects for RIC in cerebral ischemia originates from 2008, when Ren et al.[27] found 96 
that induction of a remote RIC-stimulus to the femoral artery prior to cerebral ischemia (rIPreC) 97 
reduced infarct size after focal cerebral ischemia in rats. The potential acute protective effect of 98 
rIPreC has thereafter been confirmed by numerous other studies in animals (Table 1).   99 
Whilst these previous studies highlight the potential of RIC to salvage brain injury, the 100 
unpredictability of AIS makes rIPreC not feasible for implementation as an additional therapy 101 
in stroke patients. Therefore, after the confirmation that rIPreC is a safe and effective method 102 
to protect against cerebral ischemia, the focus of researchers shifted towards the application of 103 
ischemic conditioning during (i.e. rIPerC) and after (i.e. rIPostC) AIS in animal models. One 104 
of the first studies investigating the effect of rIPostC in rats showed a reduction in infarct size 105 
of 63% when RIC was applied immediately after reperfusion, whilst a 43% reduction in infarct 106 
size was present when RIC was applied 3 hours post-stroke induction [29]. The majority of 107 
subsequent studies supported RIC’s ability to significantly reduce infarct size and improve 108 
neurological scores in rats when applied during or after focal cerebral ischemia (Table 2).  109 
 110 
Is repeated RIC effective in the animal brain?  111 
Hess et al. postulated that, in addition to the short-lasting benefits of acute RIC, long-term 112 
benefits may be induced with repeated daily conditioning [9]. A limited number of published 113 
studies have explored the effect of repeated RIC in an animal model for brain ischemia. One 114 
study found that a single episode of rIPerC afforded short-term protection, whilst brain infarct 115 
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size was further ameliorated when combined with repeated rIPostC during the 14 days after 116 
reperfusion [30]. Recently, another study provided further support for the benefits of repeated 117 
rIPostC, in that daily repeated rIPostC in a mice model was associated with a smaller infarct 118 
size and transiently improved neurological function when conditioning started up to 24 hours 119 
after reperfusion. Interestingly, even when rIPostC was started 5 days from injury and was 120 
repeated for 14 consecutive days, neurological improvement was sustained at least for 3 121 
months[31].   122 
 123 
Evidence for conditioning of the human brain  124 
Despite the potent effects of RIC to reduce infarct size in animal studies, only few clinical trials 125 
explored the effect of RIC in stroke patients (Table 3). At least, these studies show that RIC is 126 
well tolerated and has no severe adverse effects in AIS patients.[32-34] The clinical effects of RIC 127 
in humans are discussed below. 128 
 129 
Is a single bout of RIC effective in the human brain?  130 
The first study investigating the effect of single RIC in stroke patients was performed by 131 
Hougaard et al., who applied a single bout of rIPerC in ischemic stroke patients during 132 
transportation to the hospital (where they received thrombolysis within 4.5 hours)[35]. Although 133 
no effects on infarct size and growth (measured with MRI) was found, a tissue survival analysis 134 
suggested that prehospital rIPerC may have immediate neuroprotective effects.  An important 135 
practical limitation is that 18% of the patients had a transportation time too short for the full 136 
rIPerC protocol. Consequently, patients may have received a sub-optimal dose of RIC, 137 
underestimating the potential effect size of RIC. In a follow-up study (i.e. RECAST) [32], 26 138 
patients with an ischemic stroke received rIPostC within 24 hours after AIS. Interestingly, a 139 
significantly lower NIHSS after 90 days was found after rIPostC compared to placebo. Since 140 
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this study was not powered a priori to detect changes in clinical outcome (i.e. NIHSS), no 141 
definitive conclusions of the effect of rIPostC on clinical outcome can be made.  142 
 143 
Is repeated RIC effective in the human brain?  144 
Additional benefits of conditioning may be achieved by repeatedly applying RIC in stroke 145 
patients. Two randomized controlled trials examined the effect of repeated RIC in patients with 146 
intracerebral artery stenosis (ICAS). One RCT included 68 patients with stroke or TIA within 147 
the previous 30 days,[36] with the intervention group receiving RIC to the upper arm twice daily 148 
for 300 consecutive days. Incidence of recurrent stroke after 300 days in the intervention group 149 
was 7.9% versus 26.7% in the control group. RIC also significantly improved the rate of 150 
recovery, with 65.8% showing a modified Rankin Scale-score of 0-1 after 90 days versus 13.3% 151 
in the control group. Another RCT, performed by the same researchers, supported the findings 152 
of the first trial in a population of 58 symptomatic ICAS patients [37]. Two subsequent studies, 153 
performed in patients with small vessel disease, found that repeated RIC resulted in a decrease 154 
in white matter hyperintensities after one year.[38, 39] Taken together these clinical studies 155 
performed in ICAS and small vessel disease suggest that repeated RIC effectively and safely 156 
reduces the risk of recurrent stroke and supports the hypothesis that the brain demonstrates 157 
remodeling that may protect against continued cerebral ischemia.  158 
 159 
Knowledge gaps and future directions 160 
Although the preclinical evidence from studies in animals is promising and beneficial effects 161 
have been observed in clinical trials, some considerations should be discussed. First, caution is 162 
warranted for translation or extrapolation of (pre)clinical results. Related to pre-clinical studies 163 
several problems make translation to the human clinical situation difficult, including 164 
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homogeneity of the animals as opposed to heterogenous humans and the duration/severity of 165 
the ischemic lesion. To support this notion, many neuroprotectants that appeared promising in 166 
pre-clinical models have failed in clinical translation[40].  For clinical trials, it is important to 167 
realize that results from distinct subgroups of stroke patients (Table 3) cannot be simply 168 
extrapolated to the “average” stroke patient. 169 
 170 
Although some of the results from clinical studies are promising, we judged a substantial 171 
amount of these studies to be at high risk for bias (Table 4). This interpretation is in line with 172 
the assessment that was performed by Zhao et al.[13]. Important to note is that six out of the 173 
seven trials are at high risk for bias because one or two investigators had potential conflict of 174 
interest related to the automated RIC device[33, 35-39]. This leads to only one clinical study that 175 
seems to be at low risk for bias on all criteria[32]. Additionally, some form of publication bias 176 
may be present in our review. Interestingly, all studies with a relatively small sample size show 177 
a positive effect on different measures of clinical outcome (e.g. NIHSS, mRS and stroke 178 
incidence), while studies with a larger sample size show no significant effect on clinical 179 
outcome (Table 3). Therefore, we cannot exclude the potential for publication bias in this field. 180 
 181 
A final consideration is the selection of the most effective RIC protocol for AIS patients. 182 
Currently, most clinical trials adopt 3-5 cycles of 5-minutes upper-arm ischemia, with 5 minutes 183 
of reperfusion between the cycles. Although this protocol remains pragmatic,[41] it should be 184 
realized that this protocol is ‘copied’ from the area of cardiology. Whether differences in the 185 
number of cycles, duration of ischemia, location of ischemia, and/or the timing of a single RIC 186 
in relation to the ischemic event impact efficacy of RIC is currently unknown. Somewhat 187 
related is the timing of subsequent bouts to optimally benefit from repeated RIC. The current 188 
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lack of knowledge in this area highlights the need for further research, but also suggests that 189 
the optimal benefits of (repeated) RIC have yet to be determined. 190 
 191 
What can we learn from Cardiology?  192 
Since research on RIC in the field of Cardiology is a few steps ahead of Neurology, this provides 193 
an opportunity to guide the development of RIC in our area. Despite the initial successes of pre-194 
clinical work in cardiac ischemia [23], translation to the clinical setting in humans appeared 195 
challenging. For example, large randomized controlled trials found no improvement in clinical 196 
outcome and mortality in patients undergoing coronary bypass grafting (CABG)[17-19]. Likely 197 
explanations relate to the interference between RIC versus medication (e.g. statins, [21]  198 
anesthetics used in surgical procedures), aging and presence of (cardiovascular) co-199 
morbidities[42, 43]. Another important observation is that most patients scheduled for CABG 200 
have a history of angina pectoris or myocardial infarction, clinical conditions associated with 201 
short exposure to cardiac ischemia. Therefore, patients may have already been “naturally” 202 
conditioned[44]. These subject- and treatment-related factors may interfere with efficacy of RIC, 203 
and should therefore be taken into account for (ongoing) RIC trials in AIS patients. Indeed, 204 
prior TIA is associated with a reduced severity of and disability from stroke.[45-47] In line with 205 
angina pectoris, prior TIA may lead to a “naturally” conditioned status and therefore these 206 
patients may be less likely to receive additional benefits from RIC.  207 
 208 
What answers will be provided in the near future?  209 
In light of some of the evidence gaps raised above, several trials are currently ongoing to explore 210 
the effects of RIC. Upon demonstrating the feasibility and safety of RIC in AIS patients,[32, 33] 211 
follow-up trials RECAST-2 (n=60, single vs repeated RIC, NCT02779712) and REVISE-2 212 
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(n=180, CT-scan as primary outcome, NCT03045055) focus on clinical effectiveness of RIC 213 
in patients and likely provide meaningful insight into the clinical effects and/or optimal protocol 214 
for conditioning. In addition, studies also explore the benefits of applying repeated RIC in the 215 
first week after stroke onset (France; NCT02189928,[48] the Netherlands; NTR6880). Finally, 216 
Hougaard and coworkers currently perform a large (n=2,500) follow-up study of their earlier 217 
conducted trial[35]: the RESIST trial (NCT03481777), which primarily focuses on the effect of 218 
RIC on clinical parameters and control for between-patient variability. Interestingly, in addition 219 
to single RIC, the RESIST-trial will also perform repeated RIC in a subgroup of patients to 220 
explore the potential difference between single and repeated application. Individual data from 221 
these trials will help to better understand the effectiveness of RIC in AIS patients and will guide 222 
potential future implementation of RIC in clinical practice.   223 
 224 
Conclusion 225 
Recent evidence from animals and humans, including various patient groups, demonstrated that 226 
remote ischemic conditioning is a feasible and safe strategy. Moreover, pre-clinical studies in 227 
animals and initial studies in humans (including in patients), support the ability of RIC to reduce 228 
infarct size and improve clinical status when applied during (per-conditioning) or immediately 229 
after (post-conditioning) AIS. Given the hypothesis that RIC could prevent cerebral damage 230 
after the ischemic event by targeting I/R injury (which lasts for several days), RIC could even 231 
be implemented after the currently accepted treatment window for AIS of 6-24 hours. In fact, 232 
(pre)clinical studies show promising results for single and repeated conditioning, both during 233 
and after AIS. This relatively new area in stroke warrants further attention and (clinical) follow-234 
up studies, especially given the simplicity, low costs, non-invasive character and the ability of 235 
RIC to be applied without interfering with current treatment guidelines.  236 
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Figure Legends 
Figure 1. The different variants of remote ischemic conditioning and the observed effects in 
the brain. 
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Table 1. Summarized description of preclinical studies in ischemic preconditioning 
Study Animals  Randomization 
groups 
Stroke model RIC location and 
cycles 
Time of RIC (before 
stroke) 
Infarct size 
 
Neurological 
outcomes 
Quality* Physiological 
mechanism 
Zhao et al. 
2006.[49] 
SHR rats 
Male 250-350 g. 
N=87 
1: Preconditioning 
2: Sham  
3: Control 
 
Permanent 
occlusion of 
the right MCA 
and CCA.  
 
MCA. 
1x10 min 
 
24 hours  ↓ Severity of 
perfusion deficits 
↓ infarct volume 
 None 
described 
 
 
Ren et al. 
2008.[27] 
SD rats  
Male 270-330 g. 
N=60 
Different 
preconditioning 
protocols at 
different time 
windows.  
 
Permanent 
occlusion left 
distal MCA + 
occlusion 
bilateral CCA 
(30 min.) 
 
Femoral artery 
1: 2x5 min 
2: 2x15 min  
3: 3x15 min. 
1: 12 hours,  
2: 48 hours   
3: immediately before  
↓ infarct size with 
2x15 min and 3x15 
min.  
 
 Randomized  
Malhotra 
et al. 
2011.[50] 
Adult Wistar 
rats  
Male 200-225 g. 
1: rIPreC 
2: Sham surgery 
MCA 
occlusion 
(120 min.) 
Abdominal aorta 
3x10 min. 
1: 24 hours  
2: 48 hours  
3: 72 hours  
1: ↓ infarct size 
2: No effect 
3: No effect  
1: ↓ Neurological 
deficit scores 
(NDS) 
2: No effect 
3: No effect 
 
Randomized 
Blinded 
A ganglion blocker 
attenuated the 
neuroprotective 
effect. 
Yuan et 
al. 
2012.[51] 
Wistar rats  
Male 250-280 g. 
1: Sham group  
2: Control group 
3: IC of the CCA  
4: rIPreC 
 
Occlusion left 
CCA (30 
min.) + 
permanent 
occlusion left 
distal MCA 
 
Left hind limb 
3x5 min. 
Daily during the three 
days before stroke 
↓ infarct size ↑ Neurological 
scores 
Randomized 
 
Increased cerebral 
anti-oxidative 
abilities.  
Wei et al. 
2012.[52] 
SD Rats 
Male 250-350 g.  
  
1: rIPreC 
2: Control 
 
Occlusion 
bilateral CCA 
+ distal left 
MCA (30 
min.)  
 
Femoral artery 
3x15 min. 
Immediately before ↓ infarct size ↑ behavioral 
outcomes 
Randomized 
Blinded 
Through sensory 
nerves 
Hu et al. 
2012.[53] 
SD rats  
Male 280-320 g. 
N=128 
Eight different 
groups 
Occlusion 
right MCA 
(120 min.) 
Right hind limb 
3x5 min. 
1 hour  ↓ infarct size on DWI 
imaging 
↓ NDS Randomized 
 
Through adenosine 
pathway.  
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Table 2. Summarized description of preclinical studies in remote ischemic per- and postconditioning.  
Study Animals  Randomization 
groups 
Stroke model RIC location and 
cycles 
Time of RIC  Infarct size 
 
Neurological 
outcomes 
Quality* Physiological 
mechanism 
Ren et al. 
2009.[29] 
SD rats  
Male 270-330 g. 
N=37 
1: rIPostC 
2: Control 
3: Sham 
conditioning 
Permanent 
occlusion left 
distal MCA + 
occlusion 
bilateral CCA 
(30 min.) 
 
Femoral artery 
3x15 min. 
 
 
1: Immediately after 
reperfusion 
2: 3 hours after stroke 
3: 6 hours after stroke 
1: ↓ 67%  
2: ↓ 43% 
3: No effect 
 
 
 Randomized  
Blinded 
Through afferent 
nerves 
 
 
Hahn et 
al. 
2011.[54] 
 
SD rats (p60) 
Male 270-330 g.  
N=39 
1: rIPreC  
2: rIPerC 
3: Sham 
conditioning 
 
MCA 
occlusion 
(120 min). 
Left hind limb 
4x5 min.  
 
rIPreC: 40 minutes 
before ischemia 
rIPerC: during 
reperfusion 
↓ in rIPreC 
↓ in rIPerC 
 
 
 Randomized  
Ren et al. 
2011.[55] 
 
Adult SD rats  
Male 280-320 g. 
N=54 
1: rIPerC 
2: Sham 
conditioning. 
MCA 
occlusion (90 
min.) 
Femoral artery of 
the lower limb, 
bilateral. 
3x10 min.  
 
Immediately after 
stroke and before 
reperfusion 
↓ Infarct size 
↓ Brain edema 
 
 Randomized ↓ Blood-brain 
barrier leakage 
Sun et al. 
2012.[56] 
 
Adult SD rats  
Male 290-310 g. 
N=56 
7 different serials 
of RIC  
 
MCA 
occlusion (90 
min.) 
Femoral artery, 
bilateral.  
3x5 min.  
 
 
1: 3 hours after 
reperfusion 
2: 6 hours after 
reperfusion 
 
1: ↓ at 72 hours 
2: ↓ at 72 hours 
 
1: ↓ NDS 
2: ↓ NDS 
 
Randomized 
Blinded 
Through opening of 
KATP channels.  
Hoda et 
al. 
2012.[57] 
 
C57BL/6J Mice  
Male, 20 weeks 
old  
N=90 
1: rIPerC +  tPA 
2: rIPerC without 
tPA 
3: tPA only  
4. Sham treatment 
 
Thromboemb
olic 
with/without 
tPA after 4 
hours 
Left hind limb.  
5x5 min.  
 
 
2 hours after 
(embolic) stroke and 2 
hours before 
reperfusion. 
RIC alone: ↓ 25.7% 
RIC+tPA : ↓ 50% 
 
 
RIC alone: ↓ NDS 
RIC+tPA : ↓ NDS 
 
Randomized 
Blinded 
Sample size 
estimation 
Increased relative 
CBF  
Peng et al. 
2012.[58] 
 
Adult SD rats 
Male 200-250 g.   
1: Sham 
conditioning 
2: Control  
3: rIPostC 
  
Four vessel 
occlusion (8 
min.) 
Bilateral femoral 
artery.  
3x15 min.  
Immediately after 
global cerebral 
ischemia  
↓ neuronal death ↑ spatial learning  
↑ memory  
Randomized 
Blinded 
Upregulation of 
eNOS through the 
P13K/Akt pathway.  
Qi et al. 
2012.[59] 
SD rats 
Male 300-320 g.   
1: Control 
2: rIPostC  
 
MCA 
occlusion 
(120 min.) 
Bilateral femoral 
artery 
3x10 min.  
1: Immediately after 
reperfusion  
2: 10 min after 
reperfusion  
3: 30 min after 
reperfusion 
↓ Infarct volume 
 
rIPostC within 10 
min: ↑ 
neurological 
function 
 
  
Blinded A critical role for 
AKT/GSK3β-
dependent 
autophagy in 
reducing cell death. 
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Table 2. Continued.  
Study Animals  Randomization 
groups 
Stroke model RIC location and 
cycles 
Time of RIC  Infarct size 
 
Neurological 
outcomes 
Quality* Physiological 
mechanism 
Hoda et 
al. 
2014.[60] 
C57BL/6J mice 
Ovariectomized 
Female, 20 
weeks old  
N=140 
1: rIPerC +  tPA 
2: rIPerC without 
tPA 
3: tPA only  
4. Sham treatment 
 
Thromboemb
olic 
with/without 
tPA after 4 
hours 
Left hind limb 
4x10 min. 
2 hours after stroke 
and 2 hours before 
reperfusion. 
↓ infarct size  
↓ hemorrhage 
↓ edema 
↑ sensorimotor 
function 
↓ NDS 
↓ mortality  
Randomized 
Blinded 
Sample size 
estimation 
RIC improved CBF 
Cheng et 
al. 
2014.[61] 
Adult SD rats 
Male 250-300 g. 
N=45 
1: Sham operation  
2: Control  
3: rIPostC 
 
MCA 
occlusion (90 
min.) 
Right hind limb  
3x5 min.  
At the beginning of 
reperfusion 
↓ infarct size No improvement Randomized Related to neuronal 
apoptosis and 
inflammation. 
Su et al. 
2014.[62] 
SD Rats  
Male 28-320 g. 
N=168 
Seven 
experimental 
groups  
MCA 
occlusion 
(120 min.) 
Bilateral femoral 
artery 
4x10 min.  
At the beginning of 
MCA occlusion.  
↓ infarct size  
↓ edema 
↓ NDS Randomized 
Blinded 
 
Through the 
autophagy-
lysosome pathway 
 
Khan et 
al. 
2015.[63] 
C57BL/6J mice  
Male, 10 weeks 
old 
N=20 
 
1: Sham group 
2: Control group 
3: rIPostC 
 
BCAS 
induced by 
microcoils 
around both 
CCA’s.  
 
Hind limb  
4x10 min.  
1 week after induction 
of BCAS. Daily for 2 
weeks. 
 ↑ Cognitive 
function 
Randomized 
Blinded 
Sample size 
estimation 
Increased cerebral 
perfusion.  
Li et al. 
2015. [64] 
SD rats  
Male 220-280 g.  
8-10 weeks old 
1: Sham surgery 
2: Control  
3: rIPostC  
MCA 
occlusion 
(120 min.) 
Bilateral femoral 
artery 
3x10 min. 
 
Immediately after 
reperfusion.  
 ↓ NDS Randomized 
Blinded 
Attenuation of 
neuronal apoptosis 
and suppression of 
p38 MAPk-AFT2 
pathway. 
  
Ren et al. 
2015.[30] 
Adult SD rats 
Male 280-320 g.  
1: Single rIPerC 
2: rIPerC + 
repeated rIPostC 
3: Sham stroke  
4: Ischemic 
control 
MCA 
occlusion (90 
min.) 
Bilateral hind 
limb 
3x10 min.  
 
1: Single RIC: 
Immediately after 
stroke 
2: Repeated RIC: 
Immediately after 
stroke + daily 
repeated RIC during 
14 days 
 
1: ↓ infarct size after 7 
days 
2: ↓ infarct size after 7 
and 14 days 
 
 
↑ neurological 
outcome 
 
Blinded Increased 
expression of 
neuroglobin. 
Li et al. 
2015.[65]  
Adult SD rats 
Male 250-280 g.  
N=185 
1: Sham group  
2: Control group 
3: rIPostC 
 
MCA 
occlusion (60 
min.) 
Bilateral hind 
limb. 
3x10 min.  
 
During reperfusion.  ↓ infarct volume  
↓ edema 
↑ neurological 
function 
Randomized 
Blinded 
Elevation of the 
integrity of blood-
brain barrier.  
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Table 2. Continued.  
Study Animals  Randomization 
groups 
Stroke model RIC location and 
cycles 
Time of RIC  Infarct size 
 
Neurological 
outcomes 
Quality* Physiological 
mechanism 
Li et al. 
2015.[66]  
CD1 mice  
Male 25-30 g.  
N=18 
1: Sham group  
2: Control group  
3: rIPostC 
 
MCA 
occlusion (60 
min.) 
 
Bilateral femoral 
artery.  
Immediately after 
reperfusion 
↓ infarct volume  
↓ edema 
↑ neurological 
outcome 
Randomized 
Blinded 
Reduction of 
oxidative stress. 
Zong et al. 
2015[67] 
SD rats  
Male 250-280 g. 
 
1: Sham  
2: Control  
3: rIPostC 
 
MCA 
occlusion (60 
min.) 
Bilateral hind 
limb. 
At the beginning of 
reperfusion 
↓ infarct volume  
↓ edema 
↓ NDS Randomized 
Blinded 
Inhibition of HIF-
1α. 
Chen et al. 
2016.[11] 
SD rats 
Male 250-280 g.  
   
1: rIPostC 
2: Sham 
conditioning 
MCA 
occlusion (90 
min.) 
Left femoral 
artery.  
 
1: Immediately after 
reperfusion  
2: 1 hour after 
reperfusion 
3: 3 hours after 
reperfusion 
 
1: ↓ infarct volume 
2: No effect 
3: No effect 
 
1: ↑ 
Neurobehavioral 
scores 
2: No effect 
3: No effect 
 
Randomized 
Blinded 
Downregulation of 
the activation of 
NADPH oxidase in 
neutrophils.  
Wang et 
al. 
2016.[68] 
Adult SD rats 
Male 250-280 g.   
1: Sham  
2: Control 
3: rIPerC 
4: IPOC 
5: rIPerC +IPOC 
 
MCA 
occlusion 
(120 min.) 
rIPerc: left hind 
limb 
 
IPOC: MCA 
 
rIPerC: 40 min prior 
to reperfusion 
IPOC: At the 
beginning of 
reperfusion  
rIPerC + IPOC: ↓ 
infarct volume by 
>50%  
rIPerC alone: ↓ infarct 
volume by 25% 
 
 ↓ NDS Blinded Inhibition of 
autophagy  
Zhang et 
al. 
2017.[69] 
SD rats 
Male 300-320 g.   
1: Sham  
2: Control 
3: rIPostC 
 
MCA 
occlusion 
(120 min.) 
Bilateral femoral 
artery  
 
At the beginning of 
reperfusion 
↓ infarct volume  
 
↑ 
Neurobehavioral 
scores 
Blinded Suppression of 
blood brain barrier 
leakage.  
Li et al. 
2018.[70] 
SD rats 
Female 250-280 
g. 15-16 weeks  
N=81  
 
1: rIPostC 
2: Sham-stroke 
3: ischemic 
control  
 
MCA 
occlusion (60 
min.) 
Bilateral hind 
limb 
 
Immediately after 
reperfusion 
↓ infarct size by 
41.9% 
↓ edema by 27.6% 
↓ NDS Randomized  
Blinded 
Reduction of blood-
brain barrier injury 
and leakage.   
Doeppner 
et al. 
2018.[31] 
C57BL6 mice 
Male 24-28 g.  
1: rIPostC 
2: Control 
MCA 
occlusion (60 
min.) 
Bilateral hind 
limb  
1: 12 hours after 
reperfusion, repeated 
daily for 3-7 days.  
2: 24 hours after 
reperfusion 
3: 120 hours after 
reperfusion, repeated 
for 14 days  
1: ↓39.8%   
2: ↓26% 
3: ↑ neuronal density 
by 60.1% 
1: Transient 
improvement 
2: transient 
improvement 
3: Sustained 
improvement 
Randomized 
Blinded 
Mediated via HSP-
70.  
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Table 3. Summarized description of clinical studies into the effect of remote ischemic conditioning. 
Study Patients Randomization 
groups 
Location of 
RIC 
Cycles 
(occlusion/reper
fusion) 
Time of RIC Effect on infarct 
size 
 
 
Effect on 
neurological 
outcomes 
Physiological 
mechanism 
Meng et al. 
2012.[36] 
 
Patients with 
Intracranial 
arterial stenosis 
(N=68).   
 
1: Standard 
treatment only 
(N=30) 
2: RIC (N=38) 
Bilateral 
upper arm 
 5x5 min -Within 30 days after 
stroke 
-Twice daily for 300 
consecutive days. 
 ↓ Stroke 
recurrency 
↑ recovery in 
mRS 
Improvement 
in cerebral 
perfusion 
Hougaard et al. 
2014.[35] 
Patients 
suspected of an 
ischemic stroke 
(N=443).  
1: Standard 
treatment (N=196) 
2: rIPerC (N=247) 
 
Upper limb 4x5 min. During transportation 
to the hospital  
No effect on 
penumbral 
salvage or infarct 
size.  
 
↓ Tissue risk of 
infarction 
No effect (NIHSS 
and mRS) 
 
Meng et al. 
2015.[71] 
Patients with 
intracranial 
arterial stenosis 
(N=58).   
1: RIC (N=30) 
2: Sham (N=28) 
Bilateral 
upper arm 
5x5 min.  - Within 7 days after 
an ischemic stroke or 
TIA.  
- Twice daily for 180 
consecutive days 
 
  ↓ Stroke 
recurrency 
↓ NIHSS 
↓ mRS 
Reduction of 
inflammation 
and 
coagulation 
Mi et al. 2016.[39] Patients with 
cerebral small 
vessel disease 
(N=17).  
 
1: RIC (N=9) 
2: Sham (N=8) 
Bilateral 
upper arm.  
5x5 min.   Twice daily for 1 
year 
↓ White matter 
lesions 
 
No effect on 
number of lacunar 
infarcts 
 
↓ Dizziness 
handicap 
inventory 
Accelerated 
flow velocity 
in MCA.  
England et al. 
2017.[32] 
Patients with 
acute ischemic 
stroke (N=26).  
1: rIPostC (N=13) 
2: Sham (N=13) 
Upper arm 4x5 min.  Within 24 hours after 
onset of symptoms. 
  ↓ NIHSS Augmentation 
of plasma 
HSP-27.  
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Table 3. Continued.  
Study Patients Randomization 
groups 
Location of 
RIC 
Cycles 
(occlusion/reper
fusion) 
Time of RIC Effect on infarct size 
 
 
Effect on 
neurological 
outcomes 
Physiological 
mechanism 
Wang et al. 
2017.[38]  
Patients with 
cerebral small 
vessel disease-
related mild 
cognitive 
impairment 
(N=30).  
 
1: RIC (N=14) 
2: Sham (N=16) 
Bilateral 
upper arm 
5x5 min.   Twice daily for 1 
year  
↓ White matter 
hyperintensities 
↑ visuospatial and 
executive abilities 
Effect on 
triglycerides, 
cholesterol 
and 
homocysteine 
Zhao et al. 2017.[33] Patients 
undergoing 
carotid artery 
stenting 
(N=189).  
 
1: rIPreC (N=63) 
2: Sham (N=63) 
3: No intervention 
(N=63) 
Bilateral 
upper arm 
5x5 min.  Twice daily 
during two weeks 
before carotid 
artery stenting.  
↓ new DWI lesions 
↓ DWI lesions volume 
No effect on 
clinical ischemic 
events 
No changes in 
Enolase or S-
100B levels. 
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Table 4. Risk of bias assessment of clinical studies into the effect of remote ischemic conditioning 
Study Random 
sequence 
generation 
Allocation 
concealment 
Blinding of 
participants 
and personnel 
Blinding of 
outcome 
assessment 
Incomplete outcome 
data 
Selective 
reporting 
 
 
Other sources of 
bias 
Meng et al. 
2012.[36] 
 
Low Unclear High Low High Low 
 
High 
Hougaard et al. 
2014.[35] 
 
Low Unclear   High   Low   High    Low    
 
High   
Meng et al. 
2015.[71] 
 
Low   Low   Low   Low   High   Low   High   
Mi et al.  
2016.[39] 
 
Low   Unclear   Low   Low   Low   Low   
 
High   
England et al. 
2017.[32] 
 
Low   Low   Low   Low   Low   Low   Low   
Wang et al. 
2017.[38]  
 
Unclear   Unclear   Low   
 
Low High 
 
Low High 
Zhao et al.  
2017.[33] 
Low Low High Low High Low High  
 
